Because i have been looking and I must be missing something because i don't see one. Just because a stock falls doesn't mean it is a good buy there is a reason for the decline. INSIDER SELLING and cash burn and over priced. Man just look at the R and D cost.
with the recent setback in the FDA and the drop in the stock's price, the company may become an even more inviting target for a takeover. Recall a similar situation with Medarex some years ago, when that company's trial for ipilimumab ('ipi') for the treatment of metastatic melanoma yielded marginally positive results. The stock was languishing around $6-8 a share when Bristol-Myers Squibb (BMY) surprised the Street and bought the company for $16 per share. The drug is today marketed as Yervoy. Surprises do happen!
One way or the other, DVAX at current price is a superb buy. FDA will approve its vaccine's restrictive use for population from 40 to 70, as the co originally applied for. S/P will go up upon the news. In time it will be approved for those under 40, if it is not taken over by a big pharma. Such setbacks provide the opportunities to add to position for the ultimate gain within a year at most.